Sign In
Buy PRTA
$8.92
-0.270 (-2.94%)
At Close: Jun 03, 2026
Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment
11:41am, Friday, 08'th May 2026
PRTA posted a Q1 profit as a $50M Novo Nordisk milestone payment boosted revenue and improved its 2026 cash outlook.
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
04:05pm, Thursday, 07'th May 2026
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena today reported financial results for the first quarter of 2026 and provided business highlights.
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announces Novo Nordisk obtains Fast Track Designation from the U.S. FDA for coramitug (PRX004) in ATTR amyloidosis with cardiomyopathy.
Prothena Announces Leadership Team Updates
04:05pm, Friday, 10'th Apr 2026
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena promoting Ms. Kingston to Chief Strategy Officer and Mr. Isaacs to General Counsel and Corporate Secretary. Mr. Malecek is departing in June.
Wall Street Analysts Think Prothena (PRTA) Could Surge 120.19%: Read This Before Placing a Bet
10:56am, Thursday, 26'th Mar 2026
The mean of analysts' price targets for Prothena (PRTA) points to a 120.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026
04:05pm, Saturday, 21'st Mar 2026
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena partners presented clinical data updates for prasinezumab for Parkinson's and BMS-986446 for Alzheimer's disease at AD/PD™ 2026.
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena earned a $50 million milestone from Novo Nordisk related to enrollment in the Phase 3 CLEOPATTRA trial evaluating coramitug for ATTR-CM.
Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution
01:50pm, Tuesday, 03'rd Mar 2026
Prothena Corporation plc is maintained at a Hold rating due to mixed phase 2 data and long timelines for key programs. PRTA's leading assets, prasinezumab (Parkinson's disease) and coramitug (ATTR-CM)
Wall Street Analysts Believe Prothena (PRTA) Could Rally 118.09%: Here's is How to Trade
10:56am, Tuesday, 03'rd Mar 2026
The consensus price target hints at an 118.1% upside potential for Prothena (PRTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima
Prothena Announces up to $100 Million Share Repurchase Plan
04:15pm, Friday, 27'th Feb 2026
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announced its Board has authorized a Share Repurchase Plan so it may repurchase up to $100 million of the Company's outstanding shares.
Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus
12:30pm, Friday, 20'th Feb 2026
PRTA posts a narrower year-over-year Q4 loss. Revenues miss estimates, as it outlines 2026 cash burn guidance and eyes key milestones from partners.
Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript
09:24pm, Thursday, 19'th Feb 2026
Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript
Prothena (PRTA) Reports Q4 Loss, Lags Revenue Estimates
06:35pm, Thursday, 19'th Feb 2026
Prothena (PRTA) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $1.08 per share a year ago.
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
04:05pm, Thursday, 19'th Feb 2026
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights.
Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead?
10:56am, Monday, 16'th Feb 2026
PRTA stock declines 36.8% in a year as birtamimab's failure, earnings miss and reliance on partner programs weigh on investor confidence.
